this was my primary take away as well, Sarge. Don't expect Dep Doc phase II trial results any time soon, potentially not this year either.
how do we take this announcement? is it a positive that DEP trials are being further expanded, or is it a deflection tactic to announce a further delay in DEP doc phase II results... One has to question why would you hold when you can invest elsewhere and re-enter closer to announcement dates or even after a potential successful trial, when ever they may occur. I won't even comment on vivagel approvals and sales progress.
You need two lifetimes of patience to invest in SPL.
SPL Price at posting:
$1.11 Sentiment: None Disclosure: Held
